Investors

Recent Releases

May 14, 2025

Emergent BioSolutions to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md. , May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference ( New York, New York ) Fireside chat on Tuesday, May 20

May 7, 2025

Emergent BioSolutions Reports First Quarter 2025 Financial Results

First Quarter 2025 Total Revenues of $222.2 million , decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million , increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively,

May 1, 2025

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario WINNIPEG, Manitoba , May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three-year agreement with a value of approximately $65 million to supply the Ontario